LPTX vs. DTIL, ASRT, ENTX, PRLD, IZTC, CNTB, VXRT, COEP, UNCY, and CRVO
Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Precision BioSciences (DTIL), Assertio (ASRT), Entera Bio (ENTX), Prelude Therapeutics (PRLD), Invizyne Technologies (IZTC), Connect Biopharma (CNTB), Vaxart (VXRT), Coeptis Therapeutics (COEP), Unicycive Therapeutics (UNCY), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
Leap Therapeutics vs. Its Competitors
Leap Therapeutics (NASDAQ:LPTX) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by company insiders. Comparatively, 4.0% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Leap Therapeutics has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.
In the previous week, Precision BioSciences had 4 more articles in the media than Leap Therapeutics. MarketBeat recorded 8 mentions for Precision BioSciences and 4 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 0.59 beat Precision BioSciences' score of 0.40 indicating that Leap Therapeutics is being referred to more favorably in the media.
Precision BioSciences has higher revenue and earnings than Leap Therapeutics. Precision BioSciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics has a net margin of 0.00% compared to Precision BioSciences' net margin of -6,205.79%. Precision BioSciences' return on equity of -176.47% beat Leap Therapeutics' return on equity.
Leap Therapeutics presently has a consensus price target of $3.38, indicating a potential upside of 449.67%. Precision BioSciences has a consensus price target of $47.00, indicating a potential upside of 760.81%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts plainly believe Precision BioSciences is more favorable than Leap Therapeutics.
Summary
Precision BioSciences beats Leap Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Leap Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Leap Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LPTX) was last updated on 10/14/2025 by MarketBeat.com Staff
